News & Features -
Cerus Submits Final Module in Premarket Approval (PMA) Application Process for INTERCEPT Platelets
(Jul 17) More
Cerus Signs Five-Year Agreement With Belgian Red Cross Flanders for the INTERCEPT Blood System for Platelets
(May 29) More
Cerus Submits the Medical Device License Application to Health Canada for INTERCEPT Plasma
(Apr 07) More
A Single Pathogen Inactivation System for Both Platelets and Plasma
The INTERCEPT Blood System™ is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. It is the first system available to treat both platelets and plasma, and simplifies processing by utilizing the same illumination device, process and active compound. This synergistic approach is designed to meet blood center requirements for efficiency, performance and compatibility with both whole blood and apheresis collections. More
INTERCEPT eNews delivers product news & information updates right to your inbox.
This site is intended for use by healthcare professionals outside of the United States only. If you are a US resident, please see important information HERE.
The INTERCEPT Blood Systems for platelets and plasma are CE marked and produced to ISO 13485 Quality Standard.